June 2014: Life Sciences Litigation Update

by Quinn Emanuel Urquhart & Sullivan, LLP

Combination Drug Product Patent Validity. Pioneer pharmaceutical companies may have been reluctant to make the significant research and development investments required to bring combination drug products to market based on the perception that patents covering the combination would be vulnerable to attack. This perception of vulnerability stemmed from a 2007 opinion of the Supreme Court, holding that “a combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results.” KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 401 (2007). But the principle articulated in KSR does not end the validity inquiry.

In two recent cases, the Federal Circuit has upheld the validity of claims to combinations of known agents, in view of evidence that the combination provides unexpected, significant advantages over the prior art. In addition, the District of Delaware recently sustained the validity of combination drug patents in a case where the patentee was represented by the Firm. Together, these opinions may encourage companies to invest in combination drug products, leading to improved therapies for patients.

In April 2014, the Federal Circuit upheld the validity of a patent claiming the combination of an ACE inhibitor (trandolapril) and calcium channel blocker (verapamil hydrochloride) for the treatment of hypertension, in Sanofi-Aventis Deutschland GmBH v. Glenmark Pharmaceuticals Incorporated, USA, No. 12-1489, __ F.3d __, 2014 WL 1552167 (Fed. Cir. Apr. 21, 2014). The court held that substantial evidence supported the jury verdict that the alleged infringer had not proved the patent-in-suit obvious even though combinations of ACE inhibitors and calcium channel blockers were disclosed in the prior art as possible treatments for hypertension. Id. at *4-5. While the court noted that the structural dissimilarity between trandolapril and prior art ACE inhibitors supported the jury’s verdict, id. at 6, the court placed particular emphasis on the surprising evidence that the claimed combination product was superior to the prior art, noting that the combination demonstrated a better side effect profile and longer-lasting efficacy than prior art combinations of the same class of compounds at more frequent dosing intervals. See id. at *4-5.

The unexpectedly superior properties of the claimed combination distinguished Sanofi’s patent from others. See id. at *5 (distinguishing Richardson-Vicks Inc. v. Upjohn Co., 122 F.3d 1476 (Fed. Cir. 1997), holding a patent claim to a combination drug product obvious in the absence of unexpected results, from Pozen Inc. v. Par Pharmaceutical, Inc., 696 F.3d 1151 (Fed. Cir. 2012), holding a patent claim to a combination drug product nonobvious when the combination produced greater efficacy than each active ingredient on its own).

The rationale in Sanofi tracks another recent opinion of the court in Allergan Incorporated v. Sandoz Incorporated, 726 F.3d 1286, 1294 (Fed. Cir. 2013). There, the Federal Circuit sustained the validity of a claim to a method of treating glaucoma or ocular hypertension with a combination of brimonidine and timolol, relying primarily on evidence that the claimed combination was surprisingly no less effective, and had a better side effect profile, at the claimed reduced dosage amounts (twice daily administration instead of three times per day). Id. at 1293-94.

The Federal Circuit rejected the appellant’s arguments that certain disclosures in the prior art, i.e., brimonidine and timolol as single agent treatments for glaucoma in the same concentrations claimed in the patent, id. at 1290; and concurrent administration of brimonidine and timolol dosed twice per day, warranted finding the patent to be obvious. Id. at 1294. The court noted that the prior art lacked any evidence that either active ingredient in the combination produced greater efficacy or better side effects, when combined with an active from the same class of compounds as the second ingredient to the combination. See id. (“[W]e see no reason why the success of unrelated drugs would make it obvious to one of ordinary skill that a fixed combination of brimonidine and timolol could be dosed twice per day without loss of efficacy.”).

In April 2014, the Firm was also able to obtain a significant victory for innovator pharmaceutical company, Avanir Pharmaceuticals, Inc., when the company asserted its patents that covered the use of its Nuedexta® product, a combination of previously known single agents dextromethorphan (DM) and quinidine (Q) that had previously been used in combination, albeit at higher doses, by relying upon unexpected results. After a six-day bench trial before Judge Leonard P. Stark in the District of Delaware, the Court ruled in Avanir’s favor, crediting the evidence the Firm presented that skilled artisans would not have expected the use of the claimed amounts of DM and Q to be effective in treating PBA where “the dose of Q administered was reduced approximately 80-93%” from the prior-art dose, and the treatment unexpectedly remained efficacious and exhibited a better side effect profile.

The two Federal Circuit cases and the recent decision obtained by the Firm provide insight into how pioneer pharmaceutical companies can develop more solid patent protection for combination drug products before litigation ensues. The cases also provide a significant roadmap to litigation when the product covered by such patents come under attack.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Quinn Emanuel Urquhart & Sullivan, LLP | Attorney Advertising

Written by:

Quinn Emanuel Urquhart & Sullivan, LLP

Quinn Emanuel Urquhart & Sullivan, LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.